- Home
- IRON
IRON
Disc Medicine Inc.
as 10-24-2025 3:52pm EST
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 2.1B | IPO Year: | N/A |
| Target Price: | $102.23 | AVG Volume (30 days): | 623.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.82 - $95.95 | Next Earning Date: | 11-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Disc Medicine Inc. (IRON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AI DMI LLC | IRON | 10% Owner | Oct 22 '25 | Sell | $80.47 | 744,047 | $59,873,462.09 | 2,814,379 | |
| Bitterman Kevin | IRON | Director | Oct 17 '25 | Sell | $88.51 | 70,000 | $6,223,933.59 | 442,036 | |
| Bitterman Kevin | IRON | Director | Oct 16 '25 | Sell | $77.11 | 1,425 | $109,881.75 | 442,036 | |
| Bitterman Kevin | IRON | Director | Oct 15 '25 | Sell | $77.46 | 22,160 | $1,711,436.40 | 442,036 | |
| Bitterman Kevin | IRON | Director | Oct 8 '25 | Sell | $70.40 | 71,961 | $5,079,007.12 | 442,036 | |
| Bitterman Kevin | IRON | Director | Oct 7 '25 | Sell | $68.51 | 18,039 | $1,233,493.39 | 442,036 | |
| Bitterman Kevin | IRON | N/A | Aug 22 '25 | Sell | $61.03 | 2,287 | $139,575.61 | 442,036 | |
| Bitterman Kevin | IRON | N/A | Aug 14 '25 | Sell | $60.99 | 7,212 | $439,859.88 | 442,036 | |
| Bitterman Kevin | IRON | N/A | Aug 13 '25 | Sell | $61.15 | 24,962 | $1,526,426.30 | 442,036 |
Latest Disc Medicine Inc. News
IRON Breaking Stock News: Dive into IRON Ticker-Specific Updates for Smart Investing
Simply Wall St.
24 days ago
A Fresh Look at Disc Medicine’s Valuation After Bitopertin NDA Submission and Positive Phase 2 Data
MT Newswires
a month ago
Disc Medicine Submits New Drug Application to FDA for Bitopertin to Treat Patients With Erythropoietic Protoporphyria
GlobeNewswire
a month ago
Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)
Insider Monkey
4 months ago
Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target
Insider Monkey
4 months ago
Raymond James Resumes Coverage on Disc Medicine (IRON) With a Strong Buy Rating
GlobeNewswire
4 months ago
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
Investing.com
4 months ago
Raymond James bullish on biotech firms on favorable valuation
GlobeNewswire
5 months ago
Disc Medicine to Participate in Upcoming Investor Conferences
Compare IRON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRON Disc Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.